Pharmaceutical companies are investing over $1 billion in AI technologies to advance bispecific antibody development, aiming to mitigate clinical risks and manufacturing challenges. AI platforms help optimize dual-target engagement, predict immune response risks, and improve production processes, enhancing drug development efficiency in competitive oncology markets. Leading firms like Takeda, Sanofi, and Pfizer are integrating AI to accelerate R&D while navigating regulatory demands for model transparency. This shift signals a move away from traditional trial-and-error methods toward precision engineering supported by AI, with partnership-driven investments expected to drive future growth.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
